The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future.
Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.
Applications will be reviewed in the first instance by NHS England and the AHSN Network to assess deliverability and potential impact in addressing the five national diabetes priorities.
Applicants considered suitable to progress to the Diabetes Hothouse will be invited to an event on 22 November in London to present their proposals to representatives from the five pharmaceutical companies. Colleagues from both the ABPI and the AHSN Network to will be on hand to help applicants explore ideas for potential collaboration partners if support is required.
No upper or lower limit has been set for the collaboration projects. This will be based on merit, and will vary depending on both the innovation itself and how the project is designed. The decision as to whether to partner on a project will be at the discretion of the individual participating companies.
Successful applicants will be jointly supported by NHS England and the interested pharmaceutical company(ies), and the AHSN Network where required.
More on NHS England’s diabetes programme: https://www.england.nhs.uk/diabetes/